Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Abstract:
--Appointment Expands Leadership Team and Strengthens Commercial Focus--

BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Philadelphia, PA | Posted on December 2nd, 2008

BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over a decade of strategic business development experience with leading biotechnology and genomics companies. He will focus on expanding BioNanomatrix's commercial and research partnerships for its breakthrough nanoscale whole genome technology platform in multiple markets, including research, diagnostics and personalized medicine.

"Gary's background and experience are close to ideal for our newly created senior business development position, and we are very pleased to have him on board," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "Gary's scientific expertise is directly relevant to our end-user markets and his extensive business development and alliance management experience should be invaluable as we expand our network of collaborations and commercial partnerships."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.

"This is an exciting time to join BioNanomatrix as the company is advancing a potentially transformative single-molecule, whole genome sorting and imaging technology that will enable scientists to analyze clinically relevant DNA sequence variation, copy number and positional information, and to do so much faster, more cost-effectively and with far better resolution than existing methods," said Dr. Zweiger. "There are many possible applications for our technology, and I look forward to working with the BioNanomatrix team to expand the company's growing list of partnerships and help establish new opportunities for growth."

Prior to joining BioNanomatrix, Dr. Zweiger was senior director of business development at Affymetrix, where he managed collaborations, developed new business opportunities and secured revenue-generating research partnerships. Previously, he was director of business development for Applied Biosystems' Cell and Molecular Biology division, where he managed collaborations and business development activities for the company's PCR, DNA sequencing, RNA interference and cell biology businesses. Prior to Applied Biosystems, Dr. Zweiger was at Agilent Technologies, where he held positions of increasing responsibility, directing efforts to identify, assess and secure new business opportunities. Earlier in his career, Dr. Zweiger served as a strategic advisor and consultant to biotechnology and genomics companies and to the financial community. He has published a general audience book on sequencing the human genome, authored numerous scientific publications and holds seven patents. Dr. Zweiger received a Ph.D. in genetics and a B.S. in biological sciences from Stanford University and completed a post-doctoral fellowship in molecular oncology at Genentech Inc.

####

About BioNanomatrix, Inc.
BioNanomatrix isdeveloping breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.

For more information, please click here

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners
212 918-4650

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project